These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 27913932)

  • 41. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
    Capalbo C; Ricevuto E; Vestri A; Ristori E; Sidoni T; Buffone O; Adamo B; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii34-40. PubMed ID: 16760289
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants.
    Tazzite A; Jouhadi H; Nadifi S; Aretini P; Falaschi E; Collavoli A; Benider A; Caligo MA
    Gynecol Oncol; 2012 Jun; 125(3):687-92. PubMed ID: 22425665
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer.
    Prodosmo A; Buffone A; Mattioni M; Barnabei A; Persichetti A; De Leo A; Appetecchia M; Nicolussi A; Coppa A; Sciacchitano S; Giordano C; Pinnarò P; Sanguineti G; Strigari L; Alessandrini G; Facciolo F; Cosimelli M; Grazi GL; Corrado G; Vizza E; Giannini G; Soddu S
    J Exp Clin Cancer Res; 2016 Sep; 35(1):135. PubMed ID: 27599564
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence of deleterious ATM germline mutations in gastric cancer patients.
    Huang DS; Tao HQ; He XJ; Long M; Yu S; Xia YJ; Wei Z; Xiong Z; Jones S; He Y; Yan H; Wang X
    Oncotarget; 2015 Dec; 6(38):40953-8. PubMed ID: 26506520
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer.
    de Souza Timoteo AR; Gonçalves AÉMM; Sales LAP; Albuquerque BM; de Souza JES; de Moura PCP; de Aquino MAA; Agnez-Lima LF; Lajus TBP
    Breast Cancer Res Treat; 2018 Dec; 172(3):637-646. PubMed ID: 30159786
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants.
    Delgado L; Fernández G; Grotiuz G; Cataldi S; González A; Lluveras N; Heguaburu M; Fresco R; Lens D; Sabini G; Muse IM
    Breast Cancer Res Treat; 2011 Jul; 128(1):211-8. PubMed ID: 21190077
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence of Pathogenic Germline Mutations in 13 Hereditary Cancer-Related Genes in Breast Cancer Patients in Narathiwat Province, Thailand.
    Sukpan P; Kanokwiroon K; Sriplung H; Laochareonsuk W; Choochuen P; Auseng N; Wanawanakorn K; Sangkhathat S
    Asian Pac J Cancer Prev; 2023 Feb; 24(2):525-530. PubMed ID: 36853301
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families and their implications for genetic counseling.
    Palmieri G; Palomba G; Cossu A; Pisano M; Dedola MF; Sarobba MG; Farris A; Olmeo N; Contu A; Pasca A; Satta MP; Persico I; Carboni AA; Cossu-Rocca P; Contini M; Mangion J; Stratton MR; Tanda F
    Ann Oncol; 2002 Dec; 13(12):1899-907. PubMed ID: 12453858
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.
    Gomes R; Spinola PDS; Brant AC; Matta BP; Nascimento CM; de Aquino Paes SM; Bonvicino CR; Dos Santos ACE; Moreira MAM
    Breast Cancer Res Treat; 2021 Feb; 185(3):851-861. PubMed ID: 33128190
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families.
    Osorio A; Barroso A; Martínez B; Cebrián A; San Román JM; Lobo F; Robledo M; Benítez J
    Br J Cancer; 2000 Apr; 82(7):1266-70. PubMed ID: 10755399
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increased incidence of pathogenic variants in ATM in the context of testing for breast and ovarian cancer predisposition.
    Macquere P; Orazio S; Bonnet F; Jones N; Bubien V; Chiron J; Lafon D; Barouk-Simonet E; Tinat J; Venat-Bouvet L; Gesta P; Longy M; Sevenet N
    J Hum Genet; 2022 Jun; 67(6):339-345. PubMed ID: 35017683
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.
    Tedaldi G; Tebaldi M; Zampiga V; Danesi R; Arcangeli V; Ravegnani M; Cangini I; Pirini F; Petracci E; Rocca A; Falcini F; Amadori D; Calistri D
    Oncotarget; 2017 Jul; 8(29):47064-47075. PubMed ID: 28423363
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
    Määttä KM; Nurminen R; Kankuri-Tammilehto M; Kallioniemi A; Laasanen SL; Schleutker J
    BMC Cancer; 2017 Jul; 17(1):496. PubMed ID: 28738860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
    Ong PY; Poon SL; Tan KT; Putti TC; Ow SGW; Chen SJ; Chen CH; Lee SC
    Gynecol Oncol; 2019 Nov; 155(2):275-279. PubMed ID: 31481248
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
    Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N
    Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725
    [TBL] [Abstract][Full Text] [Related]  

  • 57. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
    Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
    Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Histopathological features of 'BRCAX' familial breast cancers in the kConFab resource.
    Loughrey M; Provan PJ; Byth K; ; Balleine RL
    Pathology; 2008 Jun; 40(4):352-8. PubMed ID: 18446624
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations.
    Ghimenti C; Sensi E; Presciuttini S; Brunetti IM; Conte P; Bevilacqua G; Caligo MA
    Genes Chromosomes Cancer; 2002 Mar; 33(3):235-42. PubMed ID: 11807980
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population.
    Palomba G; Loi A; Uras A; Fancello P; Piras G; Gabbas A; Cossu A; Budroni M; Contu A; Tanda F; Farris A; Orrù S; Floris C; Pisano M; Lovicu M; Santona MC; Landriscina G; Crisponi L; Palmieri G; Monne M
    BMC Cancer; 2009 Jul; 9():245. PubMed ID: 19619314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.